Anakinra, an IL-1 receptor antagonist used for rheumatoid arthritis treatment [47] and glyburide, a sulfonylurea medication inhibiting NLRP3 inflammasome activation by preventing the secretion of IL-1β [48], are just two drugs sustaining the use of NLRP3 inflammasome-targeted therapies for T2D and CMS. Here, IL1B is linked to congenital myasthenic syndrome.